» Articles » PMID: 36157216

Analysis of N6-Methyladenosine RNA Methylation Regulators in Diagnosis and Distinct Molecular Subtypes of Ankylosing Spondylitis

Overview
Journal Dis Markers
Publisher Wiley
Specialty Biochemistry
Date 2022 Sep 26
PMID 36157216
Authors
Affiliations
Soon will be listed here.
Abstract

The most frequent internal modification in eukaryotic mRNA is N6-methyladenosine (m6A). However, what we know about the m6A regulators in Ankylosing spondylitis (AS) is still limited. In our study, eight distinct m6A regulators were selected utilizing Differentially Expressed Gene (DEG) analysis of the Gene Expression Omnibus GSE73754 dataset for making comparisons between AS (Ankylosing spondylitis) and non-AS patients. The random forest model and the nomogram model were used to screen the eight candidate m6A regulators and evaluate their prediction accuracy for the occurrence of AS. Furthermore, based on the selected m6A regulators, the AS patients were divided into two subgroups, and we applied principal component analysis algorithms to calculate their m6A score and evaluate the m6A patterns. Our findings revealed that patients in cluster A were linked to activated CD4 T cell immunity and activated CD8 T cell immunity. With its major contributions in the area of immunology, our research in m6A patterns may benefit the future diagnosis and treatment strategies of AS.

Citing Articles

Identification of key genes with abnormal RNA methylation modification and selected m6A regulators in ankylosing spondylitis.

Wu F, Huang H, Sun D, Cai B, Zhou H, Quan R Immun Inflamm Dis. 2024; 12(8):e1314.

PMID: 39092763 PMC: 11295096. DOI: 10.1002/iid3.1314.


RNA methylation patterns, immune characteristics, and autophagy-related mechanisms mediated by N6-methyladenosine (m6A) regulatory factors in venous thromboembolism.

Zhang D, Fu W, Zhu S, Pan Y, Li R BMC Genomics. 2024; 25(1):403.

PMID: 38658847 PMC: 11044431. DOI: 10.1186/s12864-024-10294-2.


Exploring hub pyroptosis-related genes, molecular subtypes, and potential drugs in ankylosing spondylitis by comprehensive bioinformatics analysis and molecular docking.

Li X, Li X, Wang H, Zhao X BMC Musculoskelet Disord. 2023; 24(1):532.

PMID: 37386410 PMC: 10308648. DOI: 10.1186/s12891-023-06664-8.

References
1.
Wang R, Ward M . Epidemiology of axial spondyloarthritis: an update. Curr Opin Rheumatol. 2017; 30(2):137-143. PMC: 5811203. DOI: 10.1097/BOR.0000000000000475. View

2.
Fu Y, Dominissini D, Rechavi G, He C . Gene expression regulation mediated through reversible m⁶A RNA methylation. Nat Rev Genet. 2014; 15(5):293-306. DOI: 10.1038/nrg3724. View

3.
Lee M, Kim B, Kim V . Emerging roles of RNA modification: m(6)A and U-tail. Cell. 2014; 158(5):980-987. DOI: 10.1016/j.cell.2014.08.005. View

4.
Sieper J, Poddubnyy D . Axial spondyloarthritis. Lancet. 2017; 390(10089):73-84. DOI: 10.1016/S0140-6736(16)31591-4. View

5.
Taurog J, Chhabra A, Colbert R . Ankylosing Spondylitis and Axial Spondyloarthritis. N Engl J Med. 2016; 374(26):2563-74. DOI: 10.1056/NEJMra1406182. View